Back to Results

Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

Interested in this Trial?

Contact Us

Trial Status Recruiting

Trial Identifier

NCT07477691

Condition

Phenylketonuria

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

Study 165-401 is a Phase 4, open-label study designed to examine the concomitant use of methotrexate (MTX) to suppress immune responses to Palynziq and improve tolerability and efficacy in adults with PKU.

Eligibility Criteria

Birth Sex

All

Age

18 Years to 65 Years

Healthy Volunteers

No

Drug/Treatment:

Pegvaliase, Methotrexate

Phase:

Phase 4

Study Type:

Interventional

Number of Participants:

12

Study Started:

2026-05-29

Study Updated:

2026-06-17

Trial Locations

  • UCLA Dept. of Human Genetics

    Los Angeles, California, United States

    Trial Status Not yet recruiting

  • Children's Hospital Colorado

    Aurora, Colorado, United States

    Trial Status Not yet recruiting

  • University Of South Florida Medical Center

    Tampa, Florida, United States

    Trial Status Not yet recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, United States

    Trial Status Not yet recruiting

  • Indiana University School of Medicine

    Indianapolis, Indiana, United States

    Trial Status Not yet recruiting

  • University of Minnesota Medical School

    Minneapolis, Minnesota, United States

    Trial Status Not yet recruiting

  • University of Rochester Medical Center (URMC)

    Rochester, New York, United States

    Trial Status Not yet recruiting

  • Oregon Health & Science University (OHSU) - PARENT

    Portland, Oregon, United States

    Trial Status Not yet recruiting

  • University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh

    Philadelphia, Pennsylvania, United States

    Trial Status Not yet recruiting

  • UT Southwestern Medical Center

    Dallas, Texas, United States

    Trial Status Recruiting

    Contact

    Markey McNutt

  • University of Utah Hospital

    Salt Lake City, Utah, United States

    Trial Status Not yet recruiting

    Contact

    Markey McNutt

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin, United States

    Trial Status Not yet recruiting

    Contact

    Markey McNutt

Inclusion Criteria

  • Adults between 18 and 65 years old
  • Have a confirmed diagnosis of phenylketonuria (PKU)
  • Are in generally good health based on medical evaluation
  • Are willing and medically eligible to receive Palynziq and methotrexate (MTX) Cohort A: Have never taken Palynziq before and are willing to start it during the study Cohort B: Have blood > 600 μmol/L after taking Palynziq for at least 24 weeks, are on a daily dose of at least 20mg and unable to increase the dose further
  • Agree to use required contraception if they or their partner could become pregnant
  • Are willing to carry two epinephrine devices at all times during Palynziq treatment

Exclusion Criteria

  • Pregnant, breastfeeding, planning to become pregnant, planning to father a child, or not using effective birth control if applicable
  • Have a known severe allergy or hypersensitivity reaction to methotrexate (MTX), Palynziq, or other PEG-containing medications
  • Have a serious active infection or a history of severe or recurrent infections
  • Have significant medical conditions that may affect safety or participation (such as serious heart, lung, liver, kidney, immune, neurological, psychiatric, or cancer-related conditions)
  • Have a history of substance or alcohol abuse within the past 12 months
  • Have had an organ transplant or are taking chronic immunosuppressive medications
  • Are currently taking medications that are not allowed in the study, including other PKU treatments besides Palynziq
  • Are using, or plan to use, injectable PEG-containing medications other than Palynziq during the study
  • Have major surgery planned during the study participation period
  • Are currently participating in another clinical study involving Palynziq
  • In the opinion of the study doctor, are not a suitable candidate for the study or may have difficulty complying with study requirements

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us